Abstract: The present invention relates to a peptide comprising an amino acid sequence EX1EAX2SGSS according to SEQ ID No. 1, or a pharmaceutically acceptable salt thereof, wherein X1 and X2 independently represent a linker which links the adjoining amino acids or an amino acid deletion, and wherein the peptide has an overall length in the range of from 7 to 30 amino acids. The present invention further relates to a pharmaceutical composition comprising the peptide, and the peptide for use in the preventive treatment of acute lymphoblastic leukemia, myelodysplastic syndrome or acute myeloid leukemia, particularly therapy-related acute lymphoblastic leukemia, therapy-related myelodysplastic syndrome or therapy-related acute myeloid leukemia.

Abstract: The present invention relates to a multi-domain polypeptide comprising (i) a first complement control protein repeat (CCP)-comprising domain being a convertase decay accelerating domain for convertases of the classical and alternative pathways of complement activation, (ii) a host cell recognition domain, and (iii) a second CCP-comprising domains with cofactor activity. The present invention further relates to a polynucleotide encoding said multi-domain polypeptide, to a vector comprising said polynucleotide, and to a host cell comprising said polynucleotide and/or said vector. Further, the present invention relates to the multi-domain polypeptide, the polypeptide, and the vector for use in medicine and for treating and/or preventing inappropriate complement activation and/or a disease having inappropriate complement activation as a symptom. Moreover, the present invention relates to methods and uses related to multi-domain polypeptide, the polypeptide, and the vector.

Abstract: A method for preparing an NMR material, comprising generating parahydrogen in gas or liquid form at a first location; transporting the parahydrogen away from the first location; mixing a precursor compound including a metabolite component with a catalyst for hydrogenation; hydrogenating the precursor compound using the parahydrogen; transferring polarization in the precursor compound to a nuclear spin of the metabolite component; cleaving a side arm of the precursor compound in a chemical reaction, with the metabolite molecule being one of the products of the reaction; separating the metabolite molecule from the catalyst for hydrogenation and other products of the reaction; and generating metabolite molecules for use in an MRI scanner by extracting a sample of the metabolite molecule having at least 5% polarization.

Abstract: A method for preparing an NMR material, comprising generating parahydrogen in gas or liquid form at a first location; transporting the parahydrogen away from the first location; mixing a precursor compound including a metabolite component with a catalyst for hydrogenation; hydrogenating the precursor compound using the parahydrogen; transferring polarization in the precursor compound to a nuclear spin of the metabolite component; cleaving a side arm of the precursor compound in a chemical reaction, with the metabolite molecule being one of the products of the reaction; separating the metabolite molecule from the catalyst for hydrogenation and other products of the reaction; and generating metabolite molecules for use in an MRI scanner by extracting a sample of the metabolite molecule having at least 5% polarization.

Abstract: Disclosed is a method for analysing cells, in which cells are separated and the individual cells pass via a measurement region of a unit for spatially resolved radiation intensity measurement, wherein, for at least one of the separated cells, when passing via the measurement region, a time sequence of spatial intensity patterns of an electromagnetic radiation emitted from and/or influenced by the cell is created, the optical flow of a respective two of the spatial intensity patterns is calculated for at least one portion of the sequence of intensity patterns using a computer unit, and an evaluation of the calculated optical flows occurs. Also disclosed is a device for analysing cells, comprising a device for separating cells, a unit for spatially resolved radiation intensity measurement, and a computer unit for calculating the optical flow of a respective two of the created intensity patterns, and for evaluating the calculated optical flows.

Abstract: The invention relates to a method for providing a medication combination, wherein at least one medication of the medication combination to be provided is selected on the basis of the result of a molecular in vitro characterization of tumor tissue of a glioblastoma of a patient. The selection is made on the basis of eliminating and not selecting medications from a list of non-oncological medications for which no benefit has been acknowledged for treating the patient on the basis of the result of the molecular in vitro characterization. The medication combination which can be provided using the method is inexpensive, exhibits a low degree of toxicity, and is characterized by an improved efficacy in comparison to known medication combinations. The invention additionally relates to a data carrier with software which can support or simplify the process of carrying out the method according to the invention.

Abstract: A method for preparing an NMR material, comprising generating parahydrogen in gas or liquid form at a first location; transporting the parahydrogen away from the first location; mixing a precursor compound including a metabolite component with a catalyst for hydrogenation; hydrogenating the precursor compound using the parahydrogen; transferring polarization in the precursor compound to a nuclear spin of the metabolite component; cleaving a side arm of the precursor compound in a chemical reaction, with the metabolite molecule being one of the products of the reaction; separating the metabolite molecule from the catalyst for hydrogenation and other products of the reaction; and generating metabolite molecules for use in an MRI scanner by extracting a sample of the metabolite molecule having at least 5% polarization.

Abstract: The present invention relates to the production of bacteriocins, and in particular the production of bacteriocins of class I or II by recombinant expression in coryneform bacteria as the bacterial cell host. Also provided are modified coryneform bacteria for use as production hosts for production of bacteriocins.

Abstract: An apparatus for detecting a spatial elongation of at least one adherent biological cell is provided. The apparatus contains at least one biological cell, which is adhered to a substrate, a laser for irradiating the at least one biological cell for a spatial elongation of the cell in a direction parallel to the irradiation direction and a detector for detecting the spatial elongation of the cell in the direction parallel to the radiation direction. Further, a corresponding method for spatial elongation of an adherent biological cell is provided and the uses of the apparatus and of the method proposed. Using the apparatus and method, it is possible to ascertain, from parts of adherent cells to entire groups of adherent cells, the mechanical properties in the natural, adherent state of the cell(s) in spatially selective, temporally selective and contactless fashion.

Abstract: Disclosed is a method for analysing cells, in which cells are separated and the individual cells pass via a measurement region of a unit for spatially resolved radiation intensity measurement, wherein, for at least one of the separated cells, when passing via the measurement region, a time sequence of spatial intensity patterns of an electromagnetic radiation emitted from and/or influenced by the cell is created, the optical flow of a respective two of the spatial intensity patterns is calculated for at least one portion of the sequence of intensity patterns using a computer unit, and an evaluation of the calculated optical flows occurs. Also disclosed is a device for analysing cells, comprising a device for separating cells, a unit for spatially resolved radiation intensity measurement, and a computer unit for calculating the optical flow of a respective two of the created intensity patterns, and for evaluating the calculated optical flows.

Abstract: The invention relates to novel strategies for the treatment of cancer patients based on a combination of an opioid receptor agonist and an anticancer compound.

Abstract: A method of hyperpolarisation of nuclear spins in one or more particle(s) moving relatively to a polarisation structure, wherein a polarisation of electron spins in the polarisation structure is transferred to the nuclear spins in the particle(s), wherein for one or more of the moving particle(s) within 20 nm from a surface of the polarisation structure, the correlation time of the interaction with the nearest polarisation structure electron spin due to the molecular motion is larger than the inverse of the nuclear Larmor frequency; the electron spins in the polarisation structure are polarised above thermal equilibrium; and the polarisation transfer is performed resonantly.

Abstract: The invention relates to a method for producing a substrate structured by nanowires, characterized in that no lubricant and no lithographic resist mask is used in the method, and only by moving a donor substrate having nanowires relative to a substrate and by locally tribological properties on the surface of the substrate, a specified number of nanowires is deposited selectively at locally defined points of the substrate. The invention further relates to a substrate that can be produced using the method according to the invention, and which selectively contains a specified number of nanowires on a surface at locally defined points. The invention further relates to the use of the substrate according to the invention in microelectronics, microsystems technology, and/or micro-sensor systems.

Abstract: The invention relates to a method for producing a substrate structured by nanowires, characterized in that no lubricant and no lithographic resist mask is used in the method, and only by moving a donor substrate having nanowires relative to a substrate and by locally tribological properties on the surface of the substrate, a specified number of nanowires is deposited selectively at locally defined points of the substrate. The invention further relates to a substrate that can be produced using the method according to the invention, and which selectively contains a specified number of nanowires on a surface at locally defined points. The invention further relates to the use of the substrate according to the invention in microelectronics, microsystems technology, and/or micro-sensor systems.

Abstract: The present invention relates to the field of cell-based therapeutics. Specifically, the invention is concerned with a composition comprising a macrophage overexpressing interleukin 10 (IL-10) from transfected IL-10 encoding mRNA for use as a medicament. Moreover, a method for manufacturing a medicament for treating and/or preventing inflammation or a disease or disorder associated therewith comprising the steps of obtaining a macrophage from a sample of said subject, transfecting mRNA encoding IL-10 into said macrophage, and formulating said macrophage in a composition suitable for administration to the said subject, whereby the medicament is manufactured. Finally, a kit is provided for manufacturing such a medicament.

Abstract: The present invention relates to the field of cell-based therapeutics. Specifically, the invention is concerned with a composition comprising a macrophage overexpressing interleukin 10 (IL-10) from transfected IL-10 encoding mRNA for use as a medicament. Moreover, a method for manufacturing a medicament for treating and/or preventing inflammation or a disease or disorder associated therewith comprising the steps of obtaining a macrophage from a sample of said subject, transfecting mRNA encoding IL-10 into said macrophage, and formulating said macrophage in a composition suitable for administration to the said subject, whereby the medicament is manufactured. Finally, a kit is provided for manufacturing such a medicament.

Abstract: The invention relates to novel strategies for the treatment of cancer patients based on a combination of an opioid receptor agonist and an anticancer compound.

Abstract: DNA encoding a monomeric variant of red fluorescent protein eqFP611 comprising an amino acid sequence selected from the group consisting of SEQ ID No. 1, SEQ ID No. 3 and SEQ ID No. 5. DNA comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 2, SEQ ID No. 4 and SEQ ID No. 6.

Abstract: The use of opioids or opioid mimetics is suggested for the manufacture of a medicament for the treatment of resistant cancer patients.

Abstract: The invention relates to a composite system comprising at least one biodegradable blend, containing at least one biodegradable block copolyester urethane (PEU) and also at least one polyhydroxyalkanoate (PHA), possibly a filler comprising a polysaccharide and/or derivatives thereof and also possibly further biocompatible additives. Composite systems of this type are used for producing molded articles, molded parts or extrudates. Furthermore, the invention relates to possibilities for using the composite system.